Update on recent developments for patients with newly diagnosed multiple myeloma
Antonio Palumbo1, Valeria Magarotto, Francesca Gay
1Divisione di Ematologia dell'Università di Torino, Torino, Italy. appalumbo@yahoo.com
Annals of the New York Academy of Sciences
|October 8, 2008
Summary
Novel therapies including bortezomib or thalidomide show superior response rates compared to melphalan and prednisone (MP) for elderly multiple myeloma patients. These combinations offer promising new treatment options, challenging the standard MP regimen.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Melphalan and prednisone (MP) has been the standard treatment for elderly patients with multiple myeloma.
- There is a need for more effective therapies in this patient population.
Purpose of the Study:
- To evaluate novel therapeutic combinations as alternatives to standard MP treatment.
- To compare the efficacy of new regimens with MP in elderly multiple myeloma patients.
Main Methods:
- Review of recent studies comparing novel combination regimens with MP.
- Analysis of response rates, including complete response rates, for different treatment arms.
Main Results:
- Combination regimens containing bortezomib or thalidomide demonstrated superior response rates compared to MP alone.
- Complete response rates were notably higher in patients treated with novel combinations.
Conclusions:
- Novel therapeutic combinations, such as those with bortezomib or thalidomide, are effective alternatives to MP for elderly multiple myeloma patients.
- These newer regimens offer improved outcomes and expand treatment possibilities for this demographic.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...